Aprea Therapeutics develops cancer drugs that target specific genetic mutations in tumors. It last closed at $0.23 on Nov 20, down 53.56% on the day. The next earnings report for APRE is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, APRE reported EPS of -$0.09. Over its last 8 reports the stock moved an average of 2.6% the session after earnings. Over the last 12 months APRE insiders bought $61K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is APRE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold APRE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on APREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
APRE · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 103% below its 20 day and 156% below its 50 day average. It is 218% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $0.20, and the nearest resistance the Pivot at $0.31.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 30.9%/day
Key levels
$1.4952 week high+547.8%
$0.73200 day average+217.4%
$0.65100 day average+182.6%
$0.5950 day average+156.5%
$0.53Swing high (Nov 9)+130.4%
$0.4620 day average+100.0%
$0.42Pivot R1+82.6%
$0.31Pivot+34.8%
$0.23Last close
$0.2052 week low−13.0%
$0.12Pivot S1−47.8%
Indicators
RSI (14)
25.47
Oversold below 30
Oversold
MACD
-0.06
Below its signal line
Bearish
Stochastic
43.9
Middle of its range
Neutral
ADX (14)
32.4
Trending down
Williams %R
-92.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-305.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−55.8%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 30.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 67.3%/day
Key levels
$1.4952 week high+547.8%
$0.73200 day average+217.4%
$0.65100 day average+182.6%
$0.5950 day average+156.5%
$0.53Swing high (Nov 9)+130.4%
$0.4620 day average+100.0%
$0.42Pivot R1+82.6%
$0.31Pivot+34.8%
$0.23Last close
$0.2052 week low−13.0%
$0.12Pivot S1−47.8%
Indicators
RSI (14)
25.61
Oversold below 30
Oversold
MACD
-0.12
Below its signal line
Bearish
Stochastic
5.9
Near the bottom of its range
Oversold
ADX (14)
16.9
No clear trend
Williams %R
-97.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-210.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−70.4%
Change over 10 sessions
Bearish
ATR (14)
$0.15
Typical daily range, 67.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for APRE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how APRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow APRE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for APREHow many large options trades hit APRE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in APRE in the last 90 days.
From SEC Form 4 filings by APRE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether APRE is in one of them and how their past APRE trades turned out.
Aprea Therapeutics is a pharmaceutical company based in Doylestown, Pennsylvania, that develops cancer drugs. It focuses on treatments designed to target specific genetic mutations found in certain tumors. Its lead candidates are small molecule drugs, APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, which are in clinical trials. The company aims these treatments at patients whose cancers carry particular mutations, and its drugs are still in development.